Fitbit launched a large-scale study to validate its technology to detect atrial fibrillation

Fitbit | May 07, 2020

Fitbit launched a large-scale study to validate its technology to detect atrial fibrillation
  • Fitbit launched a sweeping heart study on Wednesday aimed at exploring whether its devices can detect atrial fibrillation.

  • The company's focus on health care, along with its work in clinical trials to alert users to conditions like hypertension and sleep apnea.

  • Fitbit's strategy is to make easy-to-use health tools that detect a range of conditions more accessible to the general population.

Wearables giant Fitbit launched a sweeping heart study on Wednesday aimed at exploring whether its devices can detect atrial fibrillation.

It's part of Fitbit's broader ambitions in healthcare to use its wearable technology for preventive health to reduce the risk of life-threatening events like stroke by detecting problems earlier.

With the launch of the heart study, Fitbit is chasing down competitor Apple which received FDA clearance in 2018 for its ECG feature and more recently launched a study with Johnson & Johnson to explore whether its own wearables can detect Afib.

"Wearable data and the kinds of information wearable data can provide will serve as another tier in the healthcare system," Eric Friedman, Fitbit co-founder and chief technology officer told FierceHealthcare.


The company's focus on health care, along with its work in clinical trials to alert users to conditions like hypertension and sleep apnea, makes it clear that it wants to pivot its wearables from just fun accessories to health devices. Fitbit’s user-generated health data, combined with the company’s analytics, can provide an "early warning sign" to users about potential problems like irregular heart rhythms suggestive of atrial fibrillation (Afib), Friedman said.

"It could serve as a 'check engine light' to help get that person to the appropriate level of care, and that could be, at first, a telehealth physician or a personal health coach. That's another layer in the healthcare system. Fitbit devices will be a "Minute Clinic' on your wrist before you have to go see a physician," he said.

Fitbit's strategy is to make easy-to-use health tools that detect a range of conditions more accessible to the general population, according to the company.

Until recently, tools for detecting AFib had a number of limitations and were only accessible if you visited a doctor, My hope is that advancing research on innovative and accessible technology, like Fitbit devices, will lead to more tools that help improve health outcomes and reduce the impact of AFib on a large scale.

- Steven Lubitz, M.D., principal investigator of the Fitbit Heart Study

Fitbit launched in 2007 and now has close to 30 million active users. In November, tech giant Google announced plans to buy the company for $2.1 billion, but that deal still needs to be approved by regulators.

Scripps Research Institute and Stanford Medicine are collaborating with Fitbit on research aimed at using Fitbit data to help detect, track and contain infectious diseases like COVID-19.

The two studies are examples of where Fitbit can fit in healthcare, Friedman said.

The heart study looks at individual wearable data to detect heart health trends and the second study looks at population-level wearable data—including heart rate, sleep, and activity levels—to try to detect the early onset of a virus.

"We're not trying to replace the healthcare system. Doctors and clinicians are dealing with acute healthcare issues and they don't have the bandwidth to look at longitudinal trends," Friedman said. "Where Fitbit wants to play and where we have value is that all-day, continuous health monitoring and guidance to help users stay healthy and manage their health conditions."

Focus on heart health

The Fitbit Heart Study aims to enroll hundreds of thousands of people, and its results will support the company’s regulatory submissions globally.

To track heart rate, Fitbit’s devices use photoplethysmography (PPG) technology to measure the rate of blood flow directly from a user’s wrist. Theoretically, these measurements can be used to determine a user’s heart rhythm, which Fitbit’s algorithm will analyze for irregularities in the Fitbit Heart Study.

Study participants who receive a notification about an irregular heart rhythm will be connected with a doctor for a virtual appointment at no cost and may receive a free electrocardiogram (ECG) patch in the mail to confirm the notification.

One of the goals of the study is to understand how wearable data and virtual care can be used as a model of healthcare that does not involve in-person care, according to Tony Faranesh, senior research scientist at Fitbit.

This model of care can be used to both offload the in-person care so the healthcare system can focus on more complicated, more acute health issues, and it's also a way of empowering and educating users about their own health and enabling them to make positive changes before they see a doctor.

- Tony Faranesh, senior research scientist at Fitbit.

AFib affects nearly 33.5 million people globally and patients with Afib have five times higher risk of stroke. But it also can be difficult to detect.

Fitbit wearables have the potential to accelerate Afib detection because the devices provide 24/7 heart rate tracking. This enables long-term heart rhythm assessment, including when users are asleep. The optimal way to identify irregular rhythm through heart rate tracking technology is to screen when the body is at rest, according to the company.

"We have the opportunity to develop and provide access to technology that may be able to improve public health and save lives," Friedman said.

Fitbit also is pursuing approval from the U.S. Food and Drug Administration and other global regulatory authorities for its Afib detection software.


Fitbit inked a multiyear partnership with pharmaceutical giants Bristol Myers Squibb and Pfizer last year to develop programs to identify and support people found to be at increased risk for stroke. Those programs will be implemented following FDA clearance for Fitbit's Afib detection software.

Fitbit completed a clinical trial of its new ECG feature for spot detection of AFib and plans to seek review by the FDA and global regulatory authorities.

About Fitbit

We're a passionate team dedicated to health and fitness who are building products that help transform people's lives. While health can be serious business, we feel it doesn't have to be. We believe you're more likely to reach your goals if you're encouraged to have fun, smile, and feel empowered along the way.


Key Messages: Recommended key learning to be acquired as appropriate for this age group based on current best evidence Alberta Learning Curriculum. Links: Where and how the key messages fit under specific Alberta Learning Curriculum objectives for teachers.

Other News

The GIANT Health Event 2021. Early bird tickets on sale now

GIANT Health | October 13, 2021

Europe's greatest festival of Health Tech Innovation | 30th Nov - 1st Dec 2021 Join us at GIANT this year and immerse yourself in Europe's greatest festival of healthcare innovation. Find inspiration from global leading innovators, and discover the advances in technology that are revolutionizing healthcare provision. GIANT 2021 is set to be our biggest event yet so don't miss out. GIANT Health event is an invaluable, cost-effective global hybrid event. Combining both a real-world physical trade show and multiple conferences in central London, as well as a sophisticated and engaging virtual event based on GIANT Health’s proprietary Virtual Event Platform. Learn more about Digital Therapeutics. Would you like to network with 1000s and 1000s of Europe's leading healthcare and technology innovators, hospital leaders, health-sector investors, and entrepreneurs? Over 400 speakers will convene in 15+ conference at the massive GIANT Health Event, 30 November - 1 December, 2021. Come join us in person or remotely. Early Bird tickets are now available. CLAIM YOUR TICKET HERE A special promotional code which allows to save up to 25% on top is available for our subscribers: MEDIA25 See you there! Media contact: GIANT Health Events Ltd Olga Nosova +44 20 8144 9779

Read More


PulsePoint Releases Next Generation Health Media Platform With Advanced Automation And AI

PulsePoint | July 06, 2021

PulsePoint, a technology company revolutionizing health decision-making in real-time, today announced the next generation launch of its digital media buying platform, Life by PulsePoint™. Its enhanced AI and automation simplifies and supercharges the media planning, activation, and optimization processes. Designed for the self-serve programmatic trader, these updates promote efficiencies and surface predictive and in-flight campaign analytics for quick strategic decisioning to yield higher media return on investment. Built upon PulsePoint's extensive data foundation, Genome™, that proactively uses microdata to capture attention when intent is signaled, Life is the leading healthcare end-to-end programmatic platform. Life's automated machine learning and AI allows marketers to quickly create highly-customized segments that classify populations in real-time, and deliver sequential messaging to drive customer actions in the moment and across the health journey. This next generation of the Life platform includes: • Advanced media planning innovations: Life offers an AI-powered forecasting tool used to run simulations to generate predictive performance metrics and intelligent audience insights. This makes it easier for marketers to preview budgets and ideate and adjust tactics to obtain their desired campaign outcomes, all before a single dollar is spent. Each forecast is powered by detailed supply and channel insights, like expected delivery, and campaign performance can be viewed by a variety of dimensions, including creative types, domains/apps, condition categories, healthcare professional specialties, geographies, among others. • Better campaign management with advanced dashboard: An automated and real-time view of line item performance and pacing gives traders a deeper, more granular look into their campaigns, making it easier for them to optimize their spend based on flight delivery and anticipate new incremental opportunities. The dashboard not only surfaces key numbers, but it also includes dynamic performance charts to uncover real-time campaign insights. • Turnkey PMP (private marketplaces) deal builder: Enhanced with turnkey end-to-end functionality, self-serve traders can now enable the deals that they negotiated directly with publishers and/or SSPs through Life's UI, decreasing the time it takes to launch PMPs. "Life was built for the healthcare marketer to simplify and optimize marketing campaigns," said Andrew Stark, CRO of PulsePoint. "Our newest capabilities increase efficiencies through advanced forecasting and real-time performance optimization, enabling more control and enhanced campaign management." Life by PulsePoint provides access to over 110 billion daily impressions across more than 2 million health pages, reaching 1.8M+ opted-in, verified healthcare professionals and over 90% of the online U.S. population. This release is just another step in PulsePoint's journey to deliver personalized messaging at each stage of the health journey using predictive insights built on real-time data. The company was recently acquired by Internet Brands, a KKR portfolio company and owner of WebMD Health Corp. PulsePoint's teams will continue to operate as their own division from their existing hubs in New York, San Francisco, and London. About PulsePoint PulsePoint is a leading technology company that uses real-world data in real-time to optimize campaign performance and revolutionize health decision-making. Leveraging proprietary datasets and methodology, PulsePoint targets healthcare professionals and patients with an unprecedented level of accuracy—delivering unparalleled results to the clients we serve.

Read More


Future Health announced today that it has completely digitalised its annual in-person event at ExCeL London

Future Health | March 02, 2021

Future Health has completely rebranded during lockdown, and the flagship face-to-face event Future Health Innovations at ExCeL is now complemented by a global virtual conference series, under the brand UK Health Week. Free for delegates to attend, it is CPD and CME accredited. Participants will be able to connect, meet buyers and partake in cross border purchasing, education and deal making, enabling an increased ROI and profitable encounters with its AI powered networking software. Further Health Weeks are being rolled out around the world over the course of the coming months, and will be territory specific. Dawn Barclay-Ross, Event Director commented: “I think there will always be a place for face-to-face events; and we are contracted with ExCeL for a live ‘in person’ event four years in advance to 2025. However, as a result of international travel restrictions, health professionals in global markets are looking for on-line engagement”. Future Health offers buyers and sellers the ability to operate on line, and to research and access the products and services that their hospitals and citizens desperately need. Dawn concluded, “In the immediate post COVID era, health buyers want to be able to operate from the comfort of their desk or smart device, and they now can, from literally anywhere in the world”. AboutFuture Health Future Health is an independent exhibition and conference organiser, based in London in the UK. For further information regarding exhibiting, visiting and sponsorship opportunities at Future Health Innovations or UK Health Week Please call +44 (0) 208 012 8511 Email: or to sign up to the Future Health platform, register at

Read More


L2Mtech GmbH Receives CE Mark Approval on 6(SIX) products for Cardiovascular and Endovascular Applications

L2Mtech | February 17, 2021

CE Mark Approval for LimusTrack™, Sirolimus Eluting Coronary Stent System for Cardiovascular Applications. CE Mark Approval for LomiFlow™, Paclitaxel Drug Eluting Balloon for Cardiovascular Applications CE Mark Approval for PearlFlow™, Paclitaxel Drug Elutin Balloon for Endovascular Applications CE Mark Approval for PearlFlow NS™, Self Expandable Nitinol Stent System for Endovascular Applications CE Mark Approval for FlexiTrack 018™, Peripheral Balloon Catheter for Endovascular Applications CE Mark Approval for FlexiTrack 035™, Peripheral Balloon Catheter for Endovascular Applications Bonn, Germany – L2Mtech GmbH has announced the award of its first CE Mark approval on Six (6) products: LimusTrack™ : Sirolimus Coated Cobalt Chromium Stent with biodegradable polymer for the treatment of coronary artery disease, de novo lesions, restenosis lesions. LomiFlow™ : Paclitaxel Coated balloon catheter for the treatment of coronary artery disease, small vessels, dilatation of de novo lesions, in-stent restenosis (ISR) cases. PearlFlow™ : Paclitaxel Coated balloon catheter for the treatment of peripheral arterial disease, PTA, dilatation of stenotic segments or lesions in peripheral arteries. PearlFlow NS™ : Self-Expanding Nitinol Stent System for the treatment of peripheral arterial disease, de novo lesions, lesions in femoropopliteal arteries. FlexiTrack 018™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in femoral, popliteal, tibial arteries. FlexiTrack 035™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in the SFA, femoral arteries. L2Mtech GmbH Founder and CEO Lalit Mamtani said ‘‘We are very excited to have been awarded our first CE Mark on six products, CE Mark approval represents a key milestone for L2Mtech GmbH and is a testament to the efficacy and safety of our innovative technology products for Cardiovascular and Endovascular applications.“ We now prepare to commercially launch the products in all markets where the CE Mark is recognized. With introduction of our innovative technology products in markets, we will be able to expand treatment options for the benefit of many millions of patients with coronary and peripheral artery disease around the world. About L2Mtech Founded in 2017, L2Mtech GmbH is a privately-owned multinational medical device company headquartered at Bonn, Germany. L2Mtech specializes in design, development, manufacture and commercialization of medical devices that are used by healthcare establishments globally. L2MTech will provide interventional physicians with innovative vascular devices including Drug Eluting Balloon manufactured in Europe.Our Core mission is to build a product portfolio focused on minimally invasive treatment for patients with cardiovascular,endovascular and vascular artery disease. For further information, please visit : Media Contact: L2Mtech GmbH +49 228 94730761

Read More


Key Messages: Recommended key learning to be acquired as appropriate for this age group based on current best evidence Alberta Learning Curriculum. Links: Where and how the key messages fit under specific Alberta Learning Curriculum objectives for teachers.